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PIEWPOINT AND COMMENTARY
linical Guidelines and Practice
n Search of the Truth
ean J. Kereiakes, MD, FACC,* Elliott M. Antman, MD, FACC†
incinnati, Ohio; and Boston, Massachusetts
Data from randomized clinical trials, non-randomized studies, and registries, as well as expert
panel consensus are appropriately weighted and woven into the context of clinical practice
guidelines. Recent guidelines for the care of patients with ischemic heart disease have
emphasized both risk stratification and early coronary angiography with revascularization of
patients with high-risk indicators. Advances in our understanding of the pathogenesis of
acute coronary syndromes and the dynamics of therapeutic innovation (improvement in
catheter-based technologies and adjunctive pharmacotherapy) mandate the timely update and
revision of practice guidelines. We believe that the weight of evidence remains clearly in
support of an early invasive treatment strategy based on risk stratification. Arguments
regarding treatment strategy (invasive vs. conservative) are misguided, and greater focus
should be placed on improving the treatment-risk paradox demonstrated in clinical practice
as well as on strategies to enhance current guideline compliance and utilization. Interest exists
in establishing regional centers of excellence for care of patients with acute ischemic heart
disease, analogous to the regionalized approach already established for patients with trauma
or stroke. This approach is supported by data that demonstrate an inverse relationship
between both institutional and operator procedural volumes and mortality, as well as by
existing constraints in resources such as specialized nurses and subspecialty-trained physi-
cians. It is appropriate at this time to briefly review specific aspects of the American College
of Cardiology/American Heart Association practice guidelines and the current process of care
for acute ischemic heart disease. (J Am Coll Cardiol 2006;48:1129–35) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.040American College of Cardiology Foundation
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rhe number of deaths in the U.S. from acute coronary
yndrome (ACS) exceeds by 7-fold that for all-cause trauma
n the general population, and for persons 65 years of age
he number is 20-fold higher (1). Based on theory developed
rom discovery science and clinical observations, controlled
linical trials evaluate new therapies and strategies for
reatment of specific patient populations. Clinical trial
vidence drives the development of clinical practice guide-
ines (CPGs), which provide recommendations to define
tandards of care (2,3). Adherence to these standards may
hen be used to estimate quality as part of a systematic
pproach to the measurement of the process of care and
utcomes.
In light of the rapidly evolving understanding of the
athogenesis of ACS, as well as the parallel evolution in
atheter-based technology and adjunctive pharmacotherapy,
t is appropriate to review the current CPGs that govern
linical practice for acute ischemic heart disease.
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Manuscript received January 18, 2006; revised manuscript received March 23,
006, accepted March 30, 2006.on–ST-segment elevation acute coronary syndrome
NSTEACS). Despite therapy with aspirin, unfractionated
r low-molecular-weight heparin, nitrates, and beta-
lockers, patients with NSTEACS remain at appreciable
isk for death (6%), recurrent myocardial infarction (MI)
11%), or need for coronary revascularization (50% to
0%) for up to 1 year following diagnosis (4). In the era
efore coronary stenting and advances in adjunctive phar-
acotherapy, CPGs promoted “conservatism” to avoid the
hazard” (periprocedural infarction, abrupt coronary closure)
ssociated with early coronary revascularization. With pro-
edural adjunctive platelet glycoprotein IIb/IIIa inhibitor
GPI) therapy to reduce periprocedural complications and
oronary stents to minimize coronary occlusion, the benefit
vs. risk) of early percutaneous coronary intervention (PCI)
as enhanced (5). Further benefit for reduction in peripro-
edural myocardial injury has been demonstrated following
oading with oral clopidogrel (6) or preprocedural treatment
ith atorvastatin (7). The introduction of drug-eluting
tents (DES) reduced angiographic and clinical restenosis
ollowing PCI in patients with ACS (8). Thus, the dynam-
cs of therapeutic innovation make CPG recommendations
“moving target.” Indeed, since publication of the most
ecent CPG for NSTEACS, considerable data have been
resented on the prevalence, pathogenesis, and clinical
elevance of clopidogrel non-responsiveness. Hypo- or non-
esponsiveness to clopidogrel has been demonstrated in 15%
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Clinical Guidelines and Practice September 19, 2006:1129–35o 31% of patients undergoing PCI who receive the stan-
ard 300 mg oral loading dose (9,10) and has been corre-
ated with the occurrence of adverse clinical events (11,12).
cceleration in the time course and extent of platelet
nhibition and reduction in the prevalence of non-
esponsiveness accompany an increase in clopidogrel oral
oading dose from 300 to 600 mg (13–15). Preliminary but
s yet inconclusive data suggest that better clinical outcomes
re also seen with higher oral loading doses of clopidogrel
6). In NSTEACS patients with an elevated troponin level
0.03 g/l) who received preprocedural clopidogrel 600
g oral load, the addition of GP IIb/IIIa inhibition with
bciximab was demonstrated to reduce periprocedural ad-
erse outcomes (25% reduction in death, MI, and urgent
arget vessel revascularization to 30 days) (16). In addition,
ome data support the benefit of “upstream” initiation of
latelet GPI therapy before PCI in NSTEACS (17,18).
he earlier initiation of GPI therapy (upstream vs. in-cath
ab) was associated with improvement in angiographic
arameters of coronary flow and myocardial perfusion.
ptimal cost efficacy (lowest cost per life-year gained) was
bserved for those patients at highest clinical risk, which
uggests that the decision to use upstream GPI may need to
e based on clinical risk stratification. Concomitant with
echnological advances, there have been improvements in
he ability to assign risk to patients presenting with
STEACS. The 2002 American College of Cardiology/
merican Heart Association (ACC/AHA) CPG update
laces considerable focus on risk stratification using a
onstellation of clinical, biochemical, and inflammatory
arkers to facilitate triage of appropriate patients to an
ptimal treatment strategy. The ACC/AHA CPG does not
ecommend indiscriminate utilization of invasive early re-
ascularization therapy for NSTEACS, as the relative ben-
fit of such treatment (vs. conservative evaluation) is directly
roportional to patient risk profile. This benefit-risk rela-
ionship has been demonstrated for the Thrombolysis in
yocardial Infarction (TIMI) Study Group, PURSUIT
Platelet Glycoprotein IIb/IIIa in Unstable Angina: Recep-
Abbreviations and Acronyms
ACC  American College of Cardiology
ACS  acute coronary syndrome
AHA  American Heart Association
CPG  clinical practice guideline
DES  drug-eluting stents
ECG  electrocardiogram
GPI  glycoprotein IIb/IIIa inhibitor
MI  myocardial infarction
NSTEACS  non–ST-segment elevation acute coronary
syndrome
RCT  randomized clinical trial
STEMI  ST-segment elevation myocardial
infarction
TIMI  Thrombolysis In Myocardial Infarctionor Suppression Using Integrilin), and GRACE (Global megistry of Acute Coronary Events) risk stratification
chemes (19). However, both the ICTUS (Invasive versus
onservative Treatment in Unstable Coronary Syndromes)
rial (20), which demonstrated no apparent benefit of a
routine” early invasive (vs. selectively invasive) treatment
trategy in NSTEACS patients for reducing the composite
linical end point of death, non-fatal MI, or rehospitaliza-
ion for angina to 1 year; as well as a meta-analysis of 7
andomized clinical trials (RCTs) (11), have questioned the
dvisability of an “early invasive” treatment strategy. We
elieve that the cumulative weight of data from RCTs
ontinues to favor the invasive (vs. conservative) treatment
trategy (Fig. 1). Furthermore, the ACC/AHA CPG clearly
ecommends risk assessment before triage for invasive treat-
ent rather than a systematic or indiscriminate approach.
learly, close scrutiny of the data is warranted.
For example, despite the inclusion of trials performed
ith antiquated technology (Veterans Affairs Non-Q Wave
nfarction Strategies In-Hospital, TIMI-IIIb), the meta-
nalysis of Mehta et al. (21) still demonstrates a highly
ignificant (p  0.001) reduction in the composite occur-
ence of death or MI following a routine (vs. selective)
nvasive treatment strategy for NSTEACS. In addition,
uestions have been raised regarding patient risk profile and
tudy methodology in the ICTUS trial (22,23). The con-
ention that a “high-risk population” was studied does not
ppear to be supported by the fact that 50% of patients
ere 65 years old, 15% had diabetes, 50% had
T-segment deviation of 0.1 mV on electrocardiogram
ECG), and 20% had troponin levels 0.10. Indeed,
espite the fact that ischemia-driven revascularization was
erformed in 54% of the conservative-strategy patients, the
umulative 1-year rate of death or non-fatal MI was 9%
sing the definition for MI employed in the TACTICS–
IMI-18 (Treat Angina with Aggrastat and Determine
ost of Therapy with an Invasive or Conservative Strategy–
hrombolysis In Myocardial Infarction-18) trial. In addi-
ion, DES technologies were not employed in the ICTUS
rial, and data on statin or clopidogrel pretreatment before
CI are not available (23). The ICTUS trial was also
nderpowered to show a mortality difference owing to its
hort duration of follow-up. In contrast, the 5-year
ollow-up of the RITA (Randomized Intervention Treat-
ent of Angina)-3 trial showed a 24% reduction in the odds
f dying in the early intervention arm (odds ratio 0.76; 95%
onfidence interval 0.58 to 1.00; p  0.054), which did not
ecome apparent until 2 years post randomization (24).
The importance of late clinical follow-up is underscored
y a meta-analysis of multiple trials with at least 6 to 12
onths follow-up, which demonstrates a significant reduc-
ion in the composite end point of death or recurrent MI as
ell as improved survival in favor of the invasive (vs.
onservative) treatment strategy for NSTEACS (25). Some
uthors who have included older trials and trials with
horter term follow-up for analysis have questioned the
agnitude of benefit attributable to an invasive (vs. conser-
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September 19, 2006:1129–35 Clinical Guidelines and Practiceative) treatment strategy (odds ratios for reduction in death
r MI 0.85; 95% confidence interval 0.69 to 1.06) (26). We
elieve the weight of evidence remains in support of early
nvasive treatment based on risk stratification. The relative
agnitude of clinical benefit observed for the invasive (vs.
onservative) strategy is directly proportional to the clinical
isk strata (TIMI, PURSUIT, GRACE) (19), serum tro-
onin elevation (27), magnitude of ST-segment shift (28),
nd age (29,30) of the patient.
We believe that arguments regarding strategy (invasive
s. conservative) are misguided and that more focus
hould be placed on the treatment-risk paradox which has
een demonstrated in practice for the early invasive
reatment strategy. Although the benefit of an early
nvasive strategy is proportional to patient risk, the
ropensity to receive such treatment appears greater in
atients at lower risk. This observation may be due to
hysician misconceptions regarding benefit-harm
radeoffs or concerns about treatment complications.
evertheless, compliance with the current ACC/AHA
PG, including early (48 h) angiography (hospital
ompliance guideline adherence quartile), is inversely
orrelated with in-hospital mortality for ACS (Fig. 2)
31). Every 10% increment in CPG adherence is associ-
ted with a 10% reduction in hospital mortality. Further-
ore, evidence-based therapies (antiplatelet agents, beta-
drenergic blockers, lipid-lowering agents, angiotensin-
onverting enzymic inhibitors) initiated before hospital
ischarge are associated with an incremental survival
dvantage in follow-up (32). The fact that performance
easures (CPG compliance) relate process of care to
ortality presents an opportunity to define strategies that
igure 1. Randomized controlled trials of invasive versus conservative trea
nfarction. The “weight” of evidence favors the invasive strategy. (Adaptednhance current CPG compliance and utilization.
s
pT-segment elevation myocardial infarction (STEMI).
he rapid restoration of normal coronary blood flow via
harmacologic or mechanical recanalization of an occluded
nfarct-related artery limits myocardial necrosis and reduces
ubsequent morbidity and mortality. The ACC/AHA CPG
or STEMI promotes reperfusion therapy (both fibrinolysis
nd PCI) and bases the choice of strategy on both resource
vailability and the anticipated time course for implement-
ng treatment (2). The relative advantage of PCI versus
brinolytic therapy is dependent on several factors. As the
trategy of primary PCI usually entails an obligate addi-
ional time delay for implementation, the advantage of PCI
vs. fibrinolysis) depends on the relative time delay to
efinitive treatment (balloon inflation). Pooled analyses of
CTs suggest that the relative survival advantage demon-
strategies for unstable angina and non–ST-segment elevation myocardial
Cannon CP, et al. Circulation 2003;107:2640.)
igure 2. Link between American College of Cardiology/American Heart
ssociation guideline adherence (hospital composite quality quartiles) and
n-hospital mortality. Every 10% increase in guideline adherence was
ssociated with a 10% reduction in in-hospital mortality (adapted from
eterson et al. [31]). *Adjusted for age, gender, body mass index, race,
nsurance status, family history of coronary disease, hypertension, diabetes,
moking, hypercholesterolemia, prior myocardial infarction/percutaneous
oronary intervention/coronary bypass surgery/congestive heart failure/
troke, renal insufficiency, blood pressure, heart rate, ST-segment shift, and
ositive cardiac biomarkers.
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Clinical Guidelines and Practice September 19, 2006:1129–35trated in favor of PCI may be lost if the PCI-related time
elay (door-to-balloon minus door-to-needle time) exceeds
ither 60 or 110 min (33,34). Differences between these
nalyses may be explained by differences in patient risk
rofile. Indeed, the absolute mortality benefit of PCI versus
brinolysis from these pooled analyses is dependent upon
ortality risk in the fibrinolytic treated patient cohorts. A
urvival advantage in favor of PCI is evident only when the
isk of death to 30 days following fibrinolysis exceeds 4%
35,36). One analysis suggests that even longer PCI-related
ime delays (exceeding 60 to 110 min) may still be associ-
ted with a PCI survival advantage in patients at highest risk
or death following fibrinolysis (21). Thus, accurate risk
ssessment should be incorporated into any STEMI treat-
ent triage algorithm.
The relative survival advantage of PCI versus fibrinolysis
s also dependent on the case volume experience of both the
perator (cardiologist) and the hospital facility (37–40).
he best clinical outcomes, and hence the greatest relative
dvantage of PCI, are obtained by the highest volume
perators and institutions. No “advantage” of PCI may be
vident in low-volume institutions. Indeed, an increase in
ortality and major adverse cardiovascular events in low-
olume (400 cases/year) PCI centers has prompted some
xperts to conclude that “tolerance of low-volume thresh-
lds for angioplasty centers with the purpose of providing
rimary PCI in acute MI should not be recommended, even
n underserved areas” (41). Transport to a center capable of
erforming PCI yields superior clinical outcomes when
ompared with onsite (community hospital) fibrinolytic
herapy when the randomization (treatment decision)-to-
alloon time approximates 90 min (42,43). Importantly, no
dverse outcomes related to transport have been observed in
housands of patients included in these analyses. Remark-
bly, the vast majority of individuals in the U.S. who
xperience STEMI live within a 60-min prehospital com-
ute from an established PCI center (44). Following DES
eployment during primary PCI for STEMI, there is a
arked reduction in angiographic and clinical restenosis,
urther enhancing the relative benefit of PCI, as optimal late
utcomes are linked to durable coronary patency. Finally,
lthough RCTs performed before the era of coronary
tenting and modern antiplatelet therapy demonstrated no
enefit for the strategy of coronary angiography and PCI
ollowing fibrinolysis (45), more recent observations (46)
nd randomized trials have consistently demonstrated im-
roved clinical outcomes with this pharmacoinvasive ap-
roach (47–49). In both the GRACIA (Routine Invasive
trategy within 24 Hours of Thrombolysis versus Ischemia
uided Conservative Approach for Acute Myocardial In-
arction with ST-Segment Elevation)-I and the SIAM
Southwest German Interventional Study in Acute Myocar-
ial Infarction)-III RCTs, the composite occurrence of
eath, recurrent MI, or revascularization was reduced by an
arly invasive strategy with coronary stenting (47,48). Sim-
larly, the REACT (Rescue Angioplasty versus Conserva- eive Treatment or Repeat Thrombolysis) trial demonstrated
hat rescue angioplasty (70% stent) after failed fibrinolytic
reatment was associated with a significant reduction in the
omposite end point occurrence of death, recurrent infarc-
ion, severe heart failure, or stroke within 6 months as
ompared with either repeated fibrinolysis or conservative
anagement (50). Again, one would expect these results to
e further enhanced if DES (now available) had been used
n the REACT trial. Furthermore, the benefit of oral
lopidogrel therapy as an adjunct to fibrinolysis appears
specially noteworthy when patients undergo catheter-based
ntervention after initial fibrinolysis (51). Finally, a meta-
nalysis of multiple randomized controlled trials evaluating
escue PCI (vs. conservative management) demonstrates a
eduction in mortality to 30 days (odds ratio 0.64; 95%
onfidence interval 0.41 to 1.00; p  0.048) (52).
Some authors have questioned the benefit of pharmaco-
ogically “facilitated” PCI for STEMI when GPI, fibrino-
ytics, or their combination are used in comparison with
rimary PCI alone (53). Subgroup analysis and pooled trial
esults suggest that earlier administration of abciximab
upstream” in the ambulance or emergency room is associ-
ted with improved pre-PCI TIMI flow grades as well as
ost-PCI TIMI myocardial blush grades and 70% ST-
egment resolution when compared with later, in-cath lab
bciximab administration at the time of PCI (54,55). Earlier
bciximab administration was accompanied by greater im-
rovement in global and regional infarct zone left ventric-
lar function as well as a trend toward improved survival
53–55). Ongoing trials evaluating upstream use of abcix-
mab should provide much needed insight into the potential
enefits of facilitated PCI.
he greater truth. Despite the preeminence of coronary
isease as a public health concern, treatment for ACS in the
.S. remains highly fragmented. In considering a more
lobal approach to ACS care, several “truths” have become
elf-evident:
olume drives proficiency. A direct relationship has been
emonstrated between both operator and facility procedural
olumes and optimal outcomes for both elective and pri-
ary PCI, as well as for coronary bypass surgery. Those
octors and hospitals performing the highest volume of
rocedures demonstrate the best outcomes, including sur-
ival. Regional centers of excellence for care of ACS should
rovide procedural volumes that are both commensurate
ith optimal outcomes and adequate to allow meaningful
easurements and comparisons between centers (56,57).
uch comparisons of quality and process measures are
ifficult among low-volume institutions.
esources are limited. We currently face a critical short-
ge of both specialized nurses and cardiovascular special-
sts (56). Patients with more complex cardiovascular
llness (congestive heart failure, MI) fare better with
ubspecialty (cardiologist) than with generalist care (57).
ne strategy for dealing with the mismatch betweenmerging evidence in favor of an interventional approach
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September 19, 2006:1129–35 Clinical Guidelines and Practicend the ability to deliver such care routinely is to
onstruct centers for ACS care. Centers for care of ACS
ould provide state-of-the-art digital radiographic
quipment, a broad inventory of PCI supplies, and
ntra-aortic balloon pumps and ancillary staff well versed
n their use and maintenance. Indeed, institutional intra-
ortic balloon pump procedural volume is inversely linked
o mortality of patients who present with STEMI com-
licated by cardiogenic shock (58). For bypass surgery,
he removal of the requirement for a certificate of need
as associated with proliferation of low-volume centers
nd a corresponding increase in mortality rate compared
ith states maintaining a certificate of need program
59). Finally, the majority (80%) of the adult popula-
ion in the U.S. are estimated to live within a 60-min
ommute from an existing PCI center (44,60). Thus, the
roliferation of multiple small programs with reduplica-
ion of services will further tax these limited resource
ools. However, it is important to evaluate the implica-
ions for community healthcare delivery if regional ACS
enters “siphon” ACS patients from local hospitals.
he prehospital care phase for ACS, especially STEMI,
s critically important. Earlier STEMI diagnosis via the
rehospital 12-lead ECG can facilitate in-hospital STEMI
reatment with either fibrinolysis or PCI. In fact, those
ospitals with the shortest door-to-balloon times incorpo-
ate prehospital diagnosis (transmitted ECG) with a mul-
idisciplinary “team” approach in which the emergency
hysician activates the catheterization laboratory before
ardiology consultation (61).
he establishment of “ACS Centers of Excellence”
hould facilitate CPG adherence (56). Data suggest our
urrent system of non-regionalized care is suboptimal in
ispensing guideline adherent care, even to high-risk
STEACS patients. Data suggest that combinations of
vidence-based therapies (antiplatelet agents, beta-blockers,
ipid-lowering agents, angiotensin-converting enzyme in-
ibitors) provide incremental survival advantage to 1 year
igure 3. Combination evidence-based therapies reduce mortality to 1 year
ollowing myocardial infarction independent of renal function. Patients
eceiving multiple clinical practice guideline-adherent medications (anti-
latelet agents, beta-blockers, lipid-lowering agents, angiotensin-
onverting enzyme inhibitors) enjoy incremental survival benefit. Adapted
rom Tay et al. (62). GFR  glomerular filtration rate; CI  confidence
nterval.ollowing STEMI (Fig. 3) (62). The comparisons of CPG
dherence and clinical outcomes among regional facilities
an contribute to the “continuous cycle” for quality improve-
ent and therapeutic development. Greater adherence to
PGs has been observed in those hospitals with higher
TEMI volumes (63). Small centers are unlikely to allocate
he resources required to optimally track, audit and report
hese measures.
specialized center approach has already been validated
n the U.S. for improving clinical outcomes for trau-
a. The lack of specialized centers for acute ischemic heart
isease is not commensurate with the magnitude of this
ublic health problem. A similar approach has been devel-
ped for establishing regional centers of care for stroke, and
credentialing process for such centers has been proposed
y the AHA. The time dependency of successful reperfu-
ion in stroke creates an even more limited window of
pportunity for brain salvage and clinical recovery. The
ollaborative spirit among community hospitals participat-
ng in integrated systems for trauma or stroke care may be
acilitated by the stark reality that both trauma and stroke
atients are frequently not profitable. Stroke patients gen-
rate few high-profit margin procedures and often have
omplicated, protracted hospital stays. The current scheme
or disproportionate cardiovascular procedural reimburse-
ent likely constrains the evolution of an optimal care
rocess for ACS, similar to those for trauma or stroke
64–66).
In the context of rapid evolution in technology, all
uidelines must be dynamic and require more frequent
pdate/revision. Current “problems” or controversies should
ot focus on the current evidence-based CPG recommen-
ations themselves, but rather on the fact that the present
ystem is inefficient in CPG implementation and adherence.
urthermore, adherence to currently available CPGs has
een correlated with improved survival. We should focus
ur efforts on mechanisms for improving and measuring
ystem performance for the implementation and adherence
o existing evidence-based guidelines that have been shown
o improve clinical outcomes (67). Only by doing so will we
rovide appropriate, quality assured care to the greatest
umber of our patients.
eprint requests and correspondence: Dr. Dean J. Kereiakes,
he Lindner Center, 2123 Auburn Avenue, Suite 424, Cincinnati,
hio 45219. E-mail: lindner@fuse.net.
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